Adrenal Insufficiency and COVID-19 Vaccination

Patients with adrenal insufficiency who are on glucocorticoid replacement therapy face unique challenges when it comes to vaccination. In most cases, conventional vaccines like those for the influenza virus don't necessitate an increase in glucocorticoid dose. However, with the advent of COVID-19 mRNA vaccines, there have been reported cases of adrenal crisis in patients with secondary adrenal insufficiency. A new paper explores three cases that shed light on this issue. 

Case 1: Idiopathic Isolated ACTH Deficiency

A 78-year-old man with idiopathic isolated ACTH deficiency received the second dose of the BNT162b2 mRNA vaccine. He decided not to take hydrocortisone (HC) on the day of vaccination. The following day, he experienced fatigue, nausea, vomiting, and appetite loss. He did not receive HC and ended up in the emergency department two days later, with severe general fatigue, nausea, vomiting, hyponatremia, and relative hypotension. His symptoms resolved a day after administration of prednisolone sodium succinate (20 mg) IV, followed by HC (100 mg) and saline infusion.

Case 2: Hypopituitarism Post-Craniopharyngioma Surgery

An 80-year-old man with anterior hypopituitarism received the first dose of the BNT162b2 mRNA vaccine. He experienced fatigue and appetite loss the morning after vaccination. Despite being afebrile, he continued his maintenance dose of HC. Five days later, he was admitted to the emergency department with severe symptoms. He was treated with HC (100 mg) IV, followed by HC (100 mg) and continuous saline infusion and felt better three days after. 

Case 3: Idiopathic Isolated ACTH Deficiency with Co-Morbidities

A 79-year-old man with idiopathic isolated ACTH deficiency received the second dose of the BNT162b2 mRNA vaccine. He developed a fever and experienced fatigue and appetite loss. An antipyretic was administered, but his symptoms persisted. A few days later an increased dose of HC (30 mg/d) was administered, following which his symptoms resolved and sodium level normalized. 

These cases highlight the importance of appropriate precautions for patients with adrenal insufficiency when receiving COVID-19 vaccines.

REFERENCE

Kurematsu Y, Mohri T, Okada S, Takahashi Y. Adrenal Crisis Associated With COVID-19 Vaccination in Patients With Adrenal Insufficiency. JCEM Case Rep. 2023 Aug 14;1(4):luad079. doi: 10.1210/jcemcr/luad079. PMCID: PMC10580477.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

Navigating the Tripledemic: JN.1, RSV, and Flu Update

Image
The respiratory viruses are out there.  Wastewater viral activity levels for COVID-19 , as reported by the Centers for Disease Control and Prevention, have reached the highest point since the Omicron surge in 2022. The levels are also high in Canada . The three primary respiratory illnesses continue to circulate at very high levels. But despite the triple threat of  SARS-Cov-2, respiratory syncytial virus ( RSV ) and the flu , there is a notable lack of community attention.   JN.1 (Pirola,  BA.2.86 ,  with additional L455S mutation, descending from a  de-escalated  variant of concern BA.2), initially detected on August 25 2023, has evolved from a variant under monitoring to a  variant of interest. Variants like Acrux (XBB.2.3, that began to spread worldwide soon after WHO declared the end of the pandemic) are  no longer relevant , but a few now less prevalent variants such as  Centaurus  (BA.2.75) and XBB, a hybrid of Centaurus with BA.2 lineage, that  gave rise to  Eris , its descend
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more